Similar articles

• IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.

  Oertel WH, Schwarz J, Tatsch K, Arnold G, Gasser T, Kirsch CM. Oertel WH, et al. Adv Neurol. 1993;60:519-24. Adv Neurol. 1993. PMID: 8420182
• 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.

  Wenning GK, Donnemiller E, Granata R, Riccabona G, Poewe W. Wenning GK, et al. Mov Disord. 1998 May;13(3):438-45. doi: 10.1002/mds.870130311. Mov Disord. 1998. PMID: 9613734
• Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.

  Verstappen CC, Bloem BR, Haaxma CA, Oyen WJ, Horstink MW. Verstappen CC, et al. Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):502-7. doi: 10.1007/s00259-006-0258-4. Epub 2006 Oct 20. Eur J Nucl Med Mol Imaging. 2007. PMID: 17053905
• Significance of non-presynaptic SPECT tracer methods in Parkinson's disease.

  Leenders KL. Leenders KL. Mov Disord. 2003 Oct;18 Suppl 7:S39-42. doi: 10.1002/mds.10577. Mov Disord. 2003. PMID: 14531045 Review.
• Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway.

  Booij J, Berendse HW. Booij J, et al. J Neurol Sci. 2011 Nov 15;310(1-2):40-3. doi: 10.1016/j.jns.2011.07.029. Epub 2011 Aug 15. J Neurol Sci. 2011. PMID: 21840542 Review.